LLY
Eli Lilly and Company
LLY has the edge over SMTI overall, supported by lower modeled downside and stronger fundamentals.
SMTI
Sanara MedTech Inc.
SMTI trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SMTI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Under pressure |
SMTI's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SMTI PE Valuation
SMTI has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SMTI Forward outlook
There aren't enough analyst estimates for SMTI to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SMTI on earnings quality, reporting a profit while its opponent remains loss making.
SMTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$3.74 |
| Q2 2026 | -$3.72 | -$2.56 |
| Q1 2026 | -$3.90 | -$2.56 |
| Q4 2025 | -$4.36 | -$3.22 |
| Q3 2025 | -$4.22 | -$3.23 |
| Q2 2025 | -$1.16 | -$0.38 |
| Q1 2025 | -$1.34 | -$0.75 |
| Q4 2024 | -$1.14 | -$0.62 |
SMTI lost $0.48 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SMTI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SMTI on profitability, with a higher operating margin.
SMTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28.4M | +8% |
| Q2 2026 | $28.1M | +8.9% |
| Q1 2026 | $27.8M | +19% |
| Q4 2025 | $27.5M | +4.7% |
| Q3 2025 | $26.3M | +22% |
| Q2 2025 | $25.8M | +28% |
| Q1 2025 | $23.4M | +26% |
| Q4 2024 | $26.3M | +49% |
SMTI's revenue has grown year over year every quarter since late 2020: $28M last quarter, up 8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -8.6 points |
| Q2 2026 | 6.3% | +6.5 points |
| Q1 2026 | 9.5% | +18 points |
| Q4 2025 | 3.8% | +5.2 points |
| Q3 2025 | 11% | +20 points |
| Q2 2025 | -0.1% | +14 points |
| Q1 2025 | -8.9% | -0.6 points |
| Q4 2024 | -1.4% | -0.1 points |
SMTI's operating margin was 2.6% last quarter, down 8.6 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
SMTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.9M | +250% |
| Q2 2026 | $2M | +125% |
| Q1 2026 | -$2.5M | +$1.2M |
| Q4 2025 | $3.9M | +349% |
| Q3 2025 | $1.1M | -45% |
| Q2 2025 | $902.7K | +$2.4M |
| Q1 2025 | -$3.7M | -$2.1M |
| Q4 2024 | $859.9K | +$1.8M |
SMTI's free cash flow has turned positive again: $7M over the past year, against −$842,048 the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SMTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +120K shares |
| 1 year | -1.8% | -158K shares |
| 3 years | +5.4% | +451K shares |
| 5 years | +17% | +1.3M shares |
| Available history | +41% | +2.6M shares |
SMTI has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over SMTI on leverage, with a lower net debt burden relative to earnings.
SMTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.4x | Elevated |
| Q2 2026 | 2.9x | Moderate |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 6.1x | High |
| Q2 2025 | 50.4x | High |
SMTI's net debt is about 3.4 years of its operating earnings (EBITDA), down from 6.1 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SMTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.2 | Neutral |
| Stochastic | 55.3 | Neutral |
SMTI's weekly RSI is 59 (neutral) and its Stochastic is 55 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SMTI PE vs Healthcare Sector
SMTI has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SMTI on trend strength, trading above more of its moving averages.
SMTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.5 | 2.8% below |
| 20 week MA | $32.2 | 1.2% above |
| 50 week MA | $25.5 | 28% above |
| 100 week MA | $28.0 | 16% above |
| 200 week MA | $32.0 | 1.8% above |
SMTI has slipped below its 8-week average, but it's still above the other four, and 1.8% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
SMTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $51.7 | +223% |
| 2021 | $51.7 | $25.7 | -50% |
| 2022 | $25.7 | $42.8 | +66% |
| 2023 | $42.8 | $41.1 | -4% |
| 2024 | $41.1 | $33.5 | -18% |
| 2025 | $33.5 | $24.2 | -28% |
| 2026 YTD | $24.2 | $32.5 | +34% |
SMTI has the edge over LLY on returns for 2026, with the stronger performance.